用propionyl L-carnitine进行心血管疾病的代谢疗法
Naranjan S Dhalla1,2, Khushman Kaur1,3, Vijayan Elimban4
1St. Boniface Hospital, Institute of Cardiovascular Sciences Albrechtsen Research Centre, Winnipeg, Manitoba, Canada.
Canadian journal of physiology and pharmacology
|February 28, 2026
概括
普罗皮尼尔L-卡尼丁 (PPLC) 通过改善线粒体新陈代谢,减少氧化应激和纠正处理缺陷,有利于心血管健康. 这些行动有助于治疗诸如心力衰竭和外围动脉疾病等疾病.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管疾病具有共同的病理机制,包括氧化应激,处理缺陷和代谢异常.
- 普罗皮尼尔L-卡尼丁 (PPLC) 是一种具有潜在治疗益处的卡尼丁衍生物.
研究的目的:
- 为了研究Propionyl L-carnitine (PPLC) 的心血管保护作用.
- 阐明PPLC在各种心血管疾病中的益处背后的机制.
主要方法:
- 审查了临床前和临床研究.
- 研究的机制包括对离子运输 (Na+-K+ ATPase,Na+-Ca2+ 交换),处理蛋白和血管功能的影响.
主要成果:
- 在心力衰竭中,PPLC减弱了Na+-K+ ATPase抑制.
- 在糖尿病心肌病和缺血-再输液损伤中,PPLC改善了的处理.
- 在外围动脉疾病中,PPLC通过调节血管功能来增强血液流动.
结论:
- PPLC在各种心血管疾病中表现出保护作用.
- PPLC的好处来自于增强的线粒体新陈代谢,减少氧化应激,并纠正处理.
- PPLC代表了对心血管功能障碍的有前途的治疗药物.
相关概念视频
Atherosclerosis III: Management
520
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520
Lipid Catabolism
1.2K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
556
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
556
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Cardiomyopathy V: Interprofessional Care
551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Electron Transport Chain: Complex I and II
19.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.3K


